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Virtual screeningThe pandemic of SARS‐Coronavirus‐2 (Coronavirus‐19) has been progressing by the increasing trend of the
cases as well as deaths with neither vaccine nor drug is rationally used to stop the viral spread over. This study
aims to perform an integrated virtual screening of compounds that had been identified from Carica papaya -
leaves, which are proposed to be a herbal treatment for SARS‐Coronavirus‐2. The screening was initiated by
evaluating the 40 compounds from Carica papaya leaves for their drug‐like likeness property. The selected com-
pounds were then secondly screened using carcinogenic and toxicity filters. Further selected compounds were
thirdly screened for their pharmacokinetic profile and the screening was lastly performed by docking the third
selected compounds against multiple protein targets of SARS‐Coronavirus‐2 employing 3‐chymotrypsin‐like
protease (3CLpro), papain‐like protease (PLpro), RNA‐dependent‐RNA‐polymerase (RdRp), endonuclease
(EndoU), S1 and S2 region of spike protein. The results show that 20 of 40 compounds, which meet the require-
ments of drug‐like likeness, carcinogenicity‐toxicity filter, and pharmacokinetic profiles, can interact with the
multiple protein targets of SARS‐Coronavirus‐2 with the order from high to low affinity as follows:
S1 > 3CLpro > EndoU > RdRp > PLpro > S2. In conclusion, Carica papaya leaves are worth to be proposed
for further in vitro study against SARS‐Coronavirus‐2 at both molecular and cellular levels.1. Introduction
The outbreak of severe acute respiratory syndrome (SARS) Coron-
avirus 2019 (Covid‐19) has been extending across the world along
with the number of victims. As reported by WHO in 6th November
2020, there had been 219 countries, 47,596,852 cases, and
1,216,357 deaths affected by the coronavirus [1]. The fast transmis-
sion from human to human‐made the victims increase day by day
without any specific antiviral agents being applied to the infected
patients [2]. The treatment using HIV antiviral agent (lopinavir) [3],
antimalaria (chloroquine) [4], and anti‐influenza (oseltamivir) [5]
have been a little bit helping the urgent situation, however, those
could be still in trial and error since no selective drug has been discov-
ered, up to now. Currently, remdesivir is an approved re‐purposed
drug from ebola and marburg antiviral agent to Coronavirus‐19 which
is indicated for adults and adolescents (12 years old or older) with
body weight at least 40 kg [6]. The viral infection also could not be
prevented since the vaccine is still under assessment [7]. Although
China’s Sinovac Biotech appeared to be safe in a late‐stage clinical trial
in Brazil, however, it still undergoes monitoring of the adverse side
effects in the few months ahead [8].The coronavirus is structurally made of an enveloped, positive
sense, and single‐stranded RNA that belongs to the family Coron-
aviridae [9]. Like many other coronaviruses (genera alpha, beta,
and delta), the large replicase polyproteins pp1a and pp1ab are
encoded by the partially overlapping 50‐terminal orf1a/b within
the 50 two‐thirds of the genome is proteolytically cleaved into 16
putative nonstructural proteins (nsps) [10]. These putative nsps
included two viral cysteine proteases, namely, nsp3 (papain‐like pro-
tease) and nsp5 (chymotrypsin‐like, 3C‐like, or main protease),
nsp12 (RNA‐dependent RNA polymerase [RdRp]), nsp13 (helicase),
and other nsps which are likely involved in the transcription and
replication of the virus [9]. Other proteins of SARS‐Coronavirus‐2
that could be targeted are EndoU, S1, and S2. EndoU (nsp15) is a
part of the SARS‐Coronavirus‐2 replicase‐transcriptase system,
responsible for virus replication and transcription system. S1 and
S2 are regions of SARS‐Coronavirus‐2 spike protein that plays a
key role in the receptor recognition and cell membrane fusion pro-
cess. S1 domain can bind with human angiotensin‐converting
enzyme 2 (ACE2) receptor to initiate the fusion process by changing
its conformation to pre‐hairpin intermediate. This state enables the
assembly of the fusion core in the S2 region of spike protein and
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fusion [11].
To date, there is no clinically approved inhibitor of the SARS pro-
tease yet they remain in development [12]. The protease inhibitor
for a diverse virus has been existing [13] such as nelfinavir [14],
amprenavir for HIV [15], and lopinavir‐ritonavir [16] for HCV. How-
ever, the production of those protease inhibitors required a multistep
reaction which is very expensive, while we need an emergency drug
that is effective, but not costly.
A study in the past time found that biflavonoid amentoflavone
from Torreya nucifera showed significant inhibition towards SARS‐
Coronavirus 3CLpro with IC50 8.3 µM. At the subsequent study, flavo-
noids including apigenin, luteolin, and quercetin also demonstrated
IC50 280.8, 20.2, and 23.8 µM, respectively, toward the protease prov-
ing that flavonoid is a potential scaffold for SARS‐Coronavirus 3CLpro
inhibitor [17]. Recently, flavonoid namely 5,6,7‐trihydroxy‐2‐phenyl‐
4H‐chromen‐4‐one (baicalein) has been co‐crystallized with SARS‐
Coronavirus‐2 3CLpro which confirmed the such compound’s binding
site with the protease [18].
Flavonoid is known to have a pleiotropic effect meaning that is not
only a single protein that can be targeted but also can affect the mul-
tiple protein targets in the one disease pathogenesis [19]. On the other
hand, RdRp is an essential protease that catalyzes the RNA replication
while encoded in the genomes of all RNA‐containing viruses with no
DNA stage. A compound mimicking biflavonoid namely theaflavin
was marked to suppress SARS‐Coronavirus‐2 replication through
inhibiting RdRp [20].
Papaya (Carica papaya) is one of the tropical fruits known contain-
ing amino acid, protein, carbohydrate, fiber, vitamin C, and other
nutrients [21]. In particular leaves, there are at least 40 compounds
(Table S1) identified in which flavonoid and its analogs present
approximately 27% [22–25]. These flavonoids and its analogs are
including apigenin, catechin, deoxyquercetin, hesperitin, isorham-
netin, kaempferol, myricetin, naringenin, protocatechuic acid, querce-
tin, and rutin.
A molecular docking study had been conducted by Muhammad
et al., presenting seven compounds from the whole Carica papaya trees
against SARS‐Coronavirus‐2 3CLpro, PLpro, and RdRp [26]. In this
present study, we performed in silico studies presenting 40 phytocon-
stituents of Carica papaya leaves against the two proteases (3CLpro
and PLpro), RdRp, EndoU, S1, and S2 targeted protein of SARS‐
Coronavirus‐2. The study was initiated by computationally screening
those 40 compounds for their drug‐like likeness, carcinogenicity‐
toxicity, and pharmacokinetics profiles using pkCSM online tools.Fig. 1. The screening steps of 40 compounds from Carica papaya leaves in identi
Coronavirus-2.
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The 20 hits from that were then simulated separately against 3CLpro,
PLpro, RdRp, EndoU, S1, and S2 proteins of SARS‐Coronavirus‐2 using
molecular docking.2. Materials and methods
2.1. Materials
The protein model was using the SARS‐Coronavirus‐2 3D crystal
structure of 3CLpro in complex with 5,6,7‐trihydroxy‐2‐phenyl‐4H‐c
hromen‐4‐one with PDBID 6M2N [27], PLpro in complex with Ac‐
hTyr‐Dap‐Gly‐Gly‐VME (PDBID 6WX4) [28], RdRp in complex with
cofactors (nsp7 and nsp8) (PDBID 6M71) [29], apo‐EndoU (PDBID
6W01) [30], apo‐S1 (PDBID 6VXX) [31], and apo‐S2 (PDBID 6VSB)
[32]. The 3D structure of the 40 ligands was downloaded from Pub-
Chem (https://pubchem.ncbi.nlm.nih.gov/). The software being used
was Biovia Discovery Studio 2020 (www.accelrys.com),
AutodockTools1.5.6 (www.scripps.edu), AutodockVina which is
embedded in PyRx version 0.8 (https://pyrx.sourceforge.io/), and
pkCSM online tool (http://biosig.unimelb.edu.au/pkcsm/prediction).
The hardware is with specifications as followed: HP Notebook 14
CM‐0006‐AU, processor AMD Ryzen 3 2200AU, HDD 1 TB, RAM
4 GB, and OS Windows 10.
2.2. Methods
The in silico prediction was initiated by screening 40 compounds
of Carica papaya leaves collected from the PubChem database using
MW, LogP, followed by AMES test and lastly human gastrointestinal
absorption. The final screened compounds were then simulated using
molecular docking against 3CLpro, PLpro, RdRp, EndoU, S1 dan S2
(see Fig. 1).
2.3. Drug-like likeness study
Forty ligands were downloaded from https://pubchem.ncbi.nlm.
nih.gov/ and converted into SMILES files. Its Lipinski Rule properties
were individually predicted by inputting its SMILES string and the pre-
diction was done by the server. Instead of molecular weight and LogP
were the filter representing the drug‐like likeness, there are a few more
parameters in this study including the number of hydrogen bond
donor (HBD), the number of hydrogen bond acceptor (HBA), the num-
ber of rotatable bonds and the surface area, were also predicted.fying the potential of this leaves to be a natural source for combating SARS-
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Using the same protocol in section 2.1, the carcinogenic profile of
the selected compounds was represented by the AMES test result.
Instead, other parameters such as maximum tolerated dose (human)
(hMTD), hERG I inhibitor, hERG II inhibitor, oral rat acute toxicity
(LD50), oral rat chronic toxicity (LOAEL), hepatotoxicity, skin sensiti-
zation, T. pyriformis toxicity, and minnow toxicity.
2.5. Pharmacokinetics study
Using the same protocol in 2.2, the pharmacokinetic profiles (ab-
sorption, distribution, metabolism, and excretion) of the selected com-
pounds were used as the filter. Subsequently, the absorption is
influenced by water solubility, Caco2 permeability, skin permeability,
P‐glycoprotein substrate, P‐glycoprotein I inhibitor, and P‐
glycoprotein II inhibitor, instead of human gastrointestinal absorption.
The distribution is represented by VDss (human), fraction unbound
(human), blood–brain barrier (BBB) permeability, and central nervous
system (CNS) permeability. The metabolism is represented by the
CYP2D6 substrate, CYP3A4 substrate, CYP1A2 inhibitor, CYP2C19
inhibitor, CYP2C9 inhibitor, CYP2D6 inhibitor, and CYP3A4 inhibitor.
Lastly, the excretion is represented by total clearance and renal OCT2
substrate.
2.6. Molecular docking study
2.6.1. Protein preparation
The 3D protein crystal structures were downloaded from www.
rcsb.org and then uploaded in Discovery Studio. The complexed ligand
from the individual protein target was taken out from the complex and
the protein was saved as pdb file. The pdb protein file was then
uploaded into Autodocktools1.5.6 and added by polar hydrogen fol-
lowed by giving Kollman charge. The protein was then saved as pdbqt
and ready for use.3. Ligand preparation
The ligand for control docking was prepared by uploading it to
AutodockTools1.5.6, given polar and non‐polar hydrogen, Gasteiger
charge and then saved as pdbqt. The available ligands in PubChem
database (https://pubchem.ncbi.nlm.nih.gov/) were directly down-
loaded in its 3D structure followed by uploading them into Discovery
Studio and then saved as pdb file. The optimized structure in PubChem
server was reported in the published paper [33,34]. Each pdb ligands
were then uploaded into Autodocktools1.5.6 and then given gasteiger
charges. The ligands were then saved as pdbqt and ready for use.
3.0.1. Control docking
The control docking was carried by redocking the individual native
ligand into the respecting protein target with the parameters as fol-
lowed: gridbox size (25×25×25) with the center of mass
x = –33.718, y = −65.831, z = 41.2267; x = 9.4133,
y = −28.3762, z = −38.0803; and x = 113.1457, y = 115.4740,
z = 125.2150, for 3CLpro, PLpro, RdRp. The coordinate ligand being
docked into EndoU, S1 and S2, respectively: x = 113.146,
y = 115.474, z = 125.2150; x = 228.417, y = 208.3656,
z = 256.074; and x = 203.530, y = 239.600 z = 186.327. The dock-
ing was run using Autodock Vina embedded in PyRx program with
exhaustiveness = 64 covering 9 conformations for each ligand. The
binding energy result was collected in csv file, whereas the best dock-
ing pose was selected and saved in pdbqt file ready for analysis. The
control docking parameters were accepted when the RMSD value
was not greater than 2.0 Å [35].3
3.0.2. Virtual screening
The virtual screening through molecular docking of 20 ligands
against 3CLpro, PLpro and RdRp, EndoU, S1, and S2 spike proteins
of SARS‐Coronavirus‐2 was carried out using the same procedure of
the individual control docking.3.0.3. Analysis
The ligands were ranked according to the binding energy from the
lowest to the highest value. Ten top lowest free energies of binding
were then selected as the virtual hits. These virtual hits were then ana-
lyzed its molecular interaction with the binding site of the individual
protein target using Discovery Studio 2020.4. Results
The drug‐like likeness is one of the criteria for a compound to be a
drug candidate. This is well‐known with the Lipinski Rule of Five pos-
tulating that a drug should be maximum having 500 g/mol in the
molecular weight, <5 in the partition coefficient (log P), maximum
of 5 in the number of hydrogen bond donor (HBD), and lastly maxi-
mum of 10 in the number of hydrogen bond acceptor (HBA) [36]. This
rule is not 100% ensuring, however, it is guiding the drug design pro-
cess. The log P is the ratio of the concentration of the compound in n‐
octanol over its concentration in water, therefore it associates with the
balance of the compound’s solubility in water during oral dissolution
steps with its oral bioavailability of the compound in the blood system
[36]. The log P < 5 is estimated to be the ideal value when the com-
pound dissolves in our body fluid as well as its absorption through the
gastrointestinal cell membrane, and then to be transported into the
blood system. In this study, the first filter of 40 compounds from Carica
papaya leaves was shortlisting 31 compounds having the maximum
logP value less than 5 (Table S2). The second filter was, 23 of them
passed the carcinogenicity effect by showing non‐responsive toward
the AMES test (Table S3). Finally, 20 compounds having at least
30% gastrointestinal absorption as the 3rd filter were shortlisted.
Table 1 presents the 20 final selected compounds having log P are less
than 5 along with other Lipinski Rule of Five criteria.
A drug should have MW which is lower than 500 Da, log P < 5, the
number of HBD ≤ 5, the number of HBA ≤ 10, rotatable bonds ≤10,
and surface area ≤140 Å [36,37]. MW will affect the potency of the
drug which is commonly expressed in IC50. The higher of MW would
be the lower IC50, therefore, the more potent the drug. However, the
MW should not be greater than 500 considering the drug permeability
during intestinal absorption [36]. The number of HBD or HBA reflects
their polarity to interact with water during the dissolution process as
well as their molecular interaction during the pharmacodynamic step
[36]. The rotatable bonds may influence their stability during pharma-
cokinetics and the receptor binding, thus, the less rotatable chain in
the molecule should be the more stable drug to perform their activity
[36,37]. The polar surface area (SA) associates with the permeability
of drugs across the cell membrane in which the higher SA might be
poorer in cell permeability (oral bioavailability) [36,37]. Therefore,
catechin, deoxyquercetin, and deoxykaempferol are among com-
pounds which meet the Lipinski rule for drug‐like likeness.
A physical or chemical agent that exposes to an individual by caus-
ing cancer is named carcinogen, which in some carcinogenic agents,
they are associated with increasing the risk of developing specific
types of cancer [38]. For example, construction workers that are fre-
quently exposed to asbestos, a carcinogenic agent, have been strongly
linked to the development of a specific type of lung cancer called
mesothelioma [39]. Importantly, it was identified some carcinogens
from drug bearing phenacetin and azathioprine structures [40]. Table 2
Table 1
The drug-like likeness profile of 20 compounds selected from Carica papaya leaves.
Ligands Lipinski Rule Rotatable Bonds Surface area
MW log P HBD HBA
2S-sambunigrin 295.291 −0.93222 4 7 4 121.142
5,7-dimethoxycoumarin 206.197 1.8102 0 4 2 86.036
anthraquinone 208.216 2.462 0 2 0 92.536
apigenin 270.24 2.5768 3 5 1 112.519
ascorbic acid 176.124 −1.4074 4 6 2 67.321
caffeic acid 180.159 1.1956 3 3 2 74.381
caffeoyl alcohol 166.176 1.1033 3 3 2 70.219
catechin 290.271 1.5461 5 6 1 119.662
deoxykaempferol 270.24 2.5768 3 5 1 112.519
deoxyquercetin 286.239 2.2824 4 6 1 117.313
dimethoxyphenol 154.165 1.4094 1 3 2 65.183
ferulic acid 194.186 1.4986 2 3 3 81.065
kaempferol 286.239 2.2824 4 6 1 117.313
niacin 123.111 0.7798 1 2 1 51.972
p-coumaric acid 164.16 1.49 2 2 2 69.587
p-coumaroyl alcohol 150.177 1.3977 2 2 2 65.425
protocatechuic acid 154.121 0.796 3 3 1 62.341
riboflavin 376.369 −1.72356 5 9 5 152.292
R-prunasin 295.291 −0.93222 4 7 4 121.142
thiamine 265.362 0.60774 2 5 4 109.957
Table 2
The AMES test result of the 20 final selected compounds for carcinogenicity prediction along with other toxicity profiles.
Ligands Toxicity
AMES* hMTD hERG I ** hERG II ** LD50 LOAEL Hepato* SS Tp* Minnow*
2S-sambunigrin No 1.117 No No 2.714 3.316 No No 0.285 3.396
5,7-dimethoxycoumarin No 0.711 No No 2.137 2.59 No No 0.609 1.06
anthraquinone No 0.083 No No 2.316 2.2 No Yes 0.922 0.514
apigenin No 0.83 No Yes 2.423 1.753 No No 0.386 1.114
ascorbic acid No 1.987 No No 1.434 3.376 No No 0.285 3.612
caffeic acid No 0.326 No No 1.992 2.028 No No 0.034 1.587
caffeoyl alcohol No 0.289 No No 1.994 1.959 No Yes 0.326 1.941
catechin No 1.072 No No 2.261 3.212 No No 0.285 1.833
deoxykaempferol No 0.479 No No 2.428 1.977 No No 0.474 1.536
deoxyquercetin No 0.837 No No 2.651 1.592 No No 0.304 1.263
dimethoxyphenol No 1.345 No No 1.809 2.866 No No 0.252 1.212
ferulic acid No 0.475 No No 2.076 3.046 No No −0.011 1.492
kaempferol No 0.676 No No 2.698 1.658 No No 0.3 1.407
niacin No 1.168 No No 2.008 2.862 No No −0.446 2.329
p-coumaric acid No 0.338 No No 2.099 2.908 No No 0.01 1.739
p-coumaroyl alcohol No 0.729 No No 2.117 2.08 No Yes 0.033 2.118
protocatechuic acid No 0.607 No No 1.951 2.341 No No −0.136 1.955
riboflavin No 0.509 No No 1.91 3.81 Yes No 0.285 3.828
R-prunasin No 1.117 No No 2.714 3.316 No No 0.285 3.396
thiamine No 0.238 No No 2.635 1.204 Yes No 0.247 2.599
* = toxicity; ** = inhibitor
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carcinogenicity prediction along with other toxicity profiles.
Toxicity predictions are used to predict whether these compounds
having dangerous or toxic properties towards human physiology.
AMES toxicity is employed to assess compounds carcinogenicity/muta-
genic properties, therefore drug candidates should not be mutagenic or
carcinogenic [38,41]. The human maximum tolerated dose (hMTD)
used to predict the value of the toxic dose threshold in human with
the value of log hMTD for more than 0.477, are considered to be
acceptable. hERG I and II are potassium channels that mediate the
repolarizing of a cardiac action potential in humans. Inhibition of
these proteins is the main cause of long QT syndrome development
that might lead to fatal arrhythmia, hence drugs should not inhibit
these ion channels. LD50 value represents the value of the dose given
to cause 50% death of a group of rats and shows toxic potency of a
compound in which a higher value of LD50 is considered to be safer.
LOAEL (lowest‐observed‐adverse‐effect level) value shows the lowest
concentration of a compound to cause an adverse effect in human4
physiology indicated by the alteration of morphology, function,
growth, or development. The safety of a compound improves as the
LOAEL value increases. Hepatotoxicity shows the toxicity of a com-
pound to cause liver injuries which disrupt its functions. It is expected
that drug candidates should be non‐hepatotoxic as considered to be a
major safety factor in drug development. Potential dermal adverse
effects are tested using a skin sensitization test, thus a compound
should not induce allergic skin dermatitis. T. pyriformis and minnow
toxicity are both utilized to measure the value of toxic endpoints. Drug
environment safety is now taken into account to reduce the environ-
mental damage by drugs with the acceptable value of T. pyriformis and
minnow toxicity to be respectively higher than 0.5 and−0.3. Based on
the overall toxicity predictions, 2S‐sambunigrin, catechin, deoxy-
quercetin, dimethoxyphenol, and R‐prunasin are considered to have
the best safety profiles among 20 compounds (http://biosig.unimelb.
edu.au/pkcsm/prediction).
Before entering the binding site of the receptor, the drug will
undergo pharmacokinetic steps including absorption, distribution,
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absorbed from the gastrointestinal into the blood vessel through the
lipid bilayer membrane reflecting its bioavailability. Next, the mole-
cule will be distributed by the blood and further carried out into the
targetted cell bearing the receptor, while being interrupted by the
plasma‐protein binding. Some drugs will have the first pass effect by
the liver’s enzymes which are early metabolized into either active or
inactive drugs. Upon the receptor binding, the drug will give the ther-
apeutic effect while gradually be metabolized by cytochrome P450 big
family into their inactive metabolites. These metabolism products will
be excreted throughout the body. Therefore, the prediction of pharma-
cokinetics profiles before docking using the software will help to
design a compound that in one hand meets the ADME criteria, and
on the other hand, it has a good binding with the receptor. Tables
3–5 and Fig. 2 present the pharmacokinetics profile of 20 hits selected
from 40 compounds identified from the Carica papaya leaves using
pkCSM online tool.
According to Table 3, 17 compounds demonstrate more than 50%
human intestinal absorption, in which 5,7‐dimethoxycoumarin,
anthraquinone, apigenin, deoxykaempferol, dimethoxyphenol, ferulic
acid, p‐coumaric acid, p‐coumaroyl alcohol, and thiamine are among
having the best absorption profile for more than 90%. The drug prop-
erties should have water solubility represented as log S value is higher
than−4, therefore, all compounds are predicted among the good drug
properties during the dissolution step. Caco2 is also the in vitro cell
model to predict the absorption of an orally administered drug [43].
The drug should have Caco2‐permeability for more than 0.90, thus,
only eight compounds are predicted to have a high human gastroin-
testinal absorption. For a transdermal route of administration, a com-
pound should have a skin permeability for at least −2.5 or lower.
Among 20 compounds, 18 of them are suitable for a transdermal
dosage form (excluding 5,7‐dimethoxycoumarin and anthraquinone).
P‐glycoprotein (P‐gp) is a protein transport essential during pharma-
cokinetics steps. This could have either advantage in therapeutic effect
or even the contradictive ones [44]. A compound should have no P‐gp
inhibition for either P‐gp I or P‐gp II. Therefore, no compounds are
predicted to either slow down the therapeutic effect or its contraindi-
cation. In conjunction, this should be proportional with their P‐gp sub-
strate inhibition profiles.
During the distribution, a drug should have a steady state uniform
concentration while reaching up the whole tissues rather than plasmaTable 3








2S-sambunigrin −3.574 0.212 40.072
5,7-dimethoxycoumarin −3.343 1.281 99.221
anthraquinone −2.387 1.041 99.925
apigenin −2.079 1.136 91.403
ascorbic acid −0.429 −0.395 39.716
caffeic acid −1.773 −0.046 55.525
caffeoyl alcohol −1.538 1.091 68.137
catechin −2.910 −0.225 62.740
deoxykaempferol −3.405 1.139 92.943
deoxyquercetin −2.987 0.109 84.972
dimethoxyphenol −2.101 0.841 95.368
ferulic acid −1.719 0.100 94.737
kaempferol −2.986 −0.053 84.952
niacin −0.515 1.219 86.389
p-coumaric acid −1.610 1.142 93.183
p-coumaroyl alcohol −1.325 1.491 92.284
protocatechuic acid −1.675 0.805 67.889
riboflavin −1.952 −0.385 54.626
R-prunasin −2.079 0.212 40.072
thiamine −2.903 0.872 92.302
5
[45]. This is defined by the number of VDss ≥ −0.15. Among 20 com-
pounds, 8 compounds (anthraquinone, caffeoyl alcohol, catechin,
deoxykaempferol, deoxyquercetin, dimethoxyphenol, p‐coumaroyl
alcohol and thiamine) are the ones which meet this criteria. Fraction
unbound describes the amount of drug which is free from plasma pro-
tein binding associated with the total concentration ready for the
receptor binding. This should have the value of ≥0.15, therefore,
except antraquinone, apigenin, deoxykaempferol, and deoxyquercetin,
the remained compounds are available for the receptor binding which
may increase the drug activity. The BBB permeability defines the pos-
sibility of compound to cross the brain membrane which may affect
the CNS [46]. For a safe drug, these values should be <−1 and <
−3 (poorly distributed to the brain and unable to penetrate CNS)
for BBB and CNS permeability, respectively. Therefore, compounds
like 5,7‐dimethoxycoumarin and anthraquinone should be taken in a
good control to avoid the CNS either depression or excitation. Table 4
presents the distribution profile of 20 compounds identified in Carica
papaya leaves.
Drug metabolism occurs mainly in the liver which will undergo
chemical alteration to improve its excretion or elimination. There
are main six subfamilies (CYPs) that are being responsible for most
of human drug metabolism with CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP3A4, are some of the most important within these sub-
families [47]. CYP2D6 and CYP3A4 are the most significant enzymes
in overall drug metabolism, and they are also found in extrahepatic
sites such as in the brain for CYP2D6, which is responsible for drug
activity in the brain. Other example is CYP3A4 in the intestines which
is mainly affecting oral bioavailability by first‐pass metabolism. Lower
bioavailability and activity are expected for compounds that have a
high affinity towards both enzymes as substrate. CYP450 enzymes
activity can be modified by drugs, either inhibition or activation. This
is potentially causing clinical drug‐drug interactions, leading to
adverse reactions or therapeutic failures. Therefore, inhibition of these
enzymes increases the possibility of adverse drug reactions and inter-
actions. Most likely, all compounds do not act as the substrate for
CYP2D6 and CYP3A4, except anthraquinone which may act as the sub-
strate of CYP3A4. More compounds are likely inhibit the CYP1A2 but
less inhibit other CYP as shown in Table 5.
Drug excretion is a process of either eliminating or removing drugs
directly in unchanged form or its inactive form. Most drugs are









−2.744 No No No
−2.401 No No No
−2.365 Yes No No
−2.736 Yes No No
−3.478 No No No
−2.735 Yes No No
−3.047 Yes No No
−2.735 Yes No No
−2.735 Yes No No
−2.735 Yes No No
−2.504 No No No
−2.709 Yes No No
−2.735 Yes No No
−2.790 No No No
−2.566 Yes No No
−2.815 Yes No No
−2.736 Yes No No
−2.740 Yes No No
−2.744 No No No
−2.963 No No No
Table 4
The distribution profile of 20 compounds identified in Carica papaya leaves as predicted by the software.
Ligands Distribution
log VDss (human) Fraction unbound (human) BBB permeability (log BB) CNS permeability (log PS)
2S-sambunigrin −0.706 0.439 −0.929 −4.57
5,7-dimethoxycoumarin −0.141 0.37 0.274 −2.405
anthraquinone 0.251 0.118 0.252 −1.474
apigenin −0.361 0.143 −1.082 −2.195
ascorbic acid −0.264 0.808 −1.233 −4.332
caffeic acid −0.409 0.358 −0.851 −3.326
caffeoyl alcohol 0.011 0.514 −0.347 −2.526
catechin 0.675 0.187 −1.182 −3.449
deoxykaempferol 0.354 0.148 −0.864 −2.092
deoxyquercetin 0.141 0.112 −1.219 −2.378
dimethoxyphenol −0.112 0.486 −0.133 −2.092
ferulic acid −0.535 0.397 −0.263 −2.93
kaempferol −0.178 0.087 −1.361 −2.357
niacin −0.794 0.601 −0.353 −2.928
p-coumaric acid −0.602 0.421 −0.234 −2.379
p-coumaroyl alcohol 0.124 0.464 −0.183 −1.835
protocatechuic acid −0.332 0.373 −0.985 −3.333
riboflavin −0.818 0.558 −1.743 −5.243
R-prunasin −0.706 0.439 −0.929 −4.57
thiamine 0.474 0.574 −0.441 −3.022
Table 5
The interaction between 20 ligands identified from Carica papaya leaves with a diverse CYP subfaimilies.
Parameter Metabolism
CYP2D6 substrate CYP3A4 substrate CYP1A2 inhibitor CYP2C19 inhibitor CYP2C9 inhibitor CYP2D6 inhibitor CYP3A4 inhibitor
2S-sambunigrin No No No No No No No
5,7-dimethoxycoumarin No No Yes No No No No
anthraquinone No Yes Yes No No No No
apigenin No No Yes Yes Yes No Yes
ascorbic acid No No No No No No No
caffeic acid No No No No No No No
caffeoyl alcohol No No No No No No No
catechin No No No No No No No
deoxykaempferol No No Yes Yes Yes No No
deoxyquercetin No No Yes No Yes No Yes
dimethoxyphenol No No Yes No No No No
ferulic acid No No No No No No No
kaempferol No No Yes No Yes No No
niacin No No No No No No No
p-coumaric acid No No No No No No No
p-coumaroyl alcohol No No Yes No No No No
protocatechuic acid No No No No No No No
riboflavin No No No No No No No
R-prunasin No No No No No No No
thiamine No No Yes No No No No
P. Hariyono et al. Results in Chemistry 3 (2021) 100113and dosing adjustments may be needed as kidney function declines.
Total clearance is the rate at which a compound is removed from
the body i.e. excreted in the urine as a compound with a higher clear-
ance value leads to shorter half‐time and hence its effective duration
[42]. Thiamine is the fastest compound to be eliminated from the body
due to its highest total clearance. In contrast, caffeoyl alcohol is the
slowest compound to be eliminated from the body due to its lowest
total clearance.
Drugs may be passively excreted by the kidney through glomerular
filtration or actively by tubular secretion. OCT2 transporter is one of
the main renal uptake transporter to actively remove drug from blood.
It plays a key role in the removal and renal clearance of mostly cationic
drugs and endogenous compounds [48]. Inhibition of OCT2 (such as
by cimetidine) decreases OCT2‐dependent renal clearance drugs, such
as metformin, hence altering pharmacokinetics and pharmacodynam-
ics profiles that may lead to undesireable adverse effects. Interestingly,
none compounds having inhibition towards renal OCT2 substrate that
might be not having undesirable side effects. Based on the prediction,
every ligands excretion will not depend on the renal OCT2 transporter.6
The control docking results for 3CLpro and PLpro against their co‐
crystallized ligands are considered to be acceptable with a RMSD value
of its internal ligand being 0.7146 Å and 1.2141 Å, respectively. On
the other hand, the other proteins have no co‐crystallized ligand,
therefore, in this case, no control docking has been carried out for
internal validation. However, we tried to do an external validation
using remdesivir as this drug is primarily targetting RdRp, Glisoxepide
for EndoU [49], N‐(9,10‐dioxo‐9,10‐dihydroanthracene‐2‐yl)benza
mide for S1 spike protein [50], and captopril for S2 spike protein
[51] of SARS‐Coronavirus‐2. PyRx has a facility to be a site finder that
predicts the binding site of apoprotein. The binding affinity of remdi-
sivir into RdRp SARS‐Coronavirus‐2 is −6.6 kcal/mol (catalytic site),
and −8.6 kcal/mol (allosteric site) representing that the parameters
are capable to calculate the binding affinity of the selected 20 com-
pounds from Carica papaya leaves. Table S4 presents the control dock-
ing results of 3CLpro, PLpro, RdRp, EndoU, S1 dan S2 protein. At the
same time, control docking of glisoxepide (EndoU), N‐(9,10‐dioxo‐9,
10‐dihydroanthracene‐2‐yl)benzamide (S1 spike), and captopril (S2
spike) demonstrate the binding affinity of the ligand into the
Fig. 2. The histogram plot of 20 compounds identified from Carica papaya leaves against their total clearance.
P. Hariyono et al. Results in Chemistry 3 (2021) 100113corresponding target as follows: −8.2, −9.7, and −4.5 kcal/ mol,
respectively. Table 6 lists down the binding affinity of the selected
20 compounds from Carica papaya leaves.
From the docking results, 20 ligands show affinity with 3CLpro,
PLpro, RdRp, EndoU, S1 and S2 ranging in −4.5 to −7.8 kcal/mol,
−4.6 to−7.5 kcal/mol,−4.6 to−6.9 kcal/mol,−4.6 to−7.7 kcal/-
mol, −4.9 to −8.2 kcal/mol, and −4.2 to −6.3 kcal/mol, respec-
tively. These describe the most favorable interactions of the 20
ligands are to 3CLpro, EndoU, and S1, rather than PLpro, RdRp, and
S2. This is in agreement with the average of the binding affinity, in
which interaction with 3CLpro (−6.3 kcal/mol), EndoU (−6.1 kcal/-
mol), and S1 (−6.6 kcal/mol) has the lowest binding energy as men-
tioned in parentheses. Fig. 3 illustrates the overlapping 20 ligands
docked conformation in the binding site of individual 3CLpro, PLpro,
RdRp, EndoU, S1, and S2.Table 6
The binding affinity of 20 compounds identified from Carica papaya leaves upon mole
Coronavirus-2.






ascorbic acid −5.0 −4.9
caffeic acid −5.8 −5.2





ferulic acid −5.6 −5.2
kaempferol −7.2 −6.7
niacin −4.5 −4.6
p-coumaric acid −5.3 −4.8
p-coumaroyl alcohol −5.0 −4.7






In particular, on one hand, dexoyquercetin demonstrates the lowest
binding energy toward 3CLpro (‐7.8 kcal/mol), whereas catechin per-
formed the most favorable binding toward EndoU. Furthermore,
kaempferol shows the lowest binding energy toward S1 (‐8.2 kcal/
mol). On the other hand, riboflavin, kaempferol, and apigenin demon-
strate the lowest binding energy towards PLpro, RdRp and S2, respec-
tively. Figs. 4 and 5 illustrates the best binding pose of ligands into
individual protein binding sites.
The binding pose of deoxyquercetin in the 3CLpro binding site
occurs through the H‐bond interaction with GLU166 and PHE140.
Instead, the ligand pose might be stabilized by the hydrophobic inter-
action with HIS163, MET165, and GLU166. In the binding pose of
riboflavin in PLpro binding site, the H‐bond interaction occurred at
ASP302, VAL165, ARG166, TYR273, and SER245, whereas the
hydrophobic interactions were performed by interacting withcular docking study into 3CLpro, Plpro, RdRp, EndoU, S1 and S2 spike of SARS-
RdRP EndoU S1 S2
−6.5 −6.5 −7.3 −5.3
−5.4 −5.4 −6.1 −5.4
−6.4 −6.8 −7.0 −5.9
−6.5 −7.2 −7.7 −6.3
−5.4 −4.7 −5.6 −4.8
−5.7 −6.1 −6.1 −4.9
−5.1 −6 −5.9 −4.8
−6.9 −7.7 −7.8 −6.1
−6.5 −7.2 −7.8 −6.0
−6.7 −7.5 −8.0 −6.0
−4.7 −5.7 −4.9 −4.2
−5.4 −5.7 −6.1 −4.8
−6.9 −7.2 −8.2 −5.9
−4.6 −4.6 −4.9 −4.7
−5.2 −5.6 −5.9 −4.6
−4.7 −5.2 −5.3 −4.4
−5.6 −5.1 −5.8 −4.6
−6.6 −6.6 −8.1 −6.2
−6.3 −6.6 −7.1 −5.6
−6.0 −5.3 −7.0 −5.1
−5.9 −6.1 −6.6 −5.3
Fig. 3. The overlapping docked pose of 20 compounds identified from Carica papaya leaves in the binding site of a) 3CLpro, b) PLpro, c) RdRp, d) EndoU, e) S1,
and f) S2. The proteins were presented in a surface model, whereas the ligands were presented in a yellow stick model, with C, H, O, and N are colored by yellow,
white, red and blue, respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 4. The docking pose of a) deoxyquercetin (−7.8 kcal/mol) into 3CLpro, b) riboflavin into PLpro (−7.5 kcal/mol), and c) kaempferol (−6.9 kcal/mol) into
RdRp. The proteins were visualized in ribbon model, whereas the ligands were presented in a yellow stick model, with C, H, O, and N are colored by yellow, white,
red and blue, respectively. The H-bond interaction and the hydrophobic interaction are presented in black and orange dashed lines, respectively. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
P. Hariyono et al. Results in Chemistry 3 (2021) 100113PRO247, TYR268, and ARG166. Kaempferol interacts with LYS545,
THR556, ARG553, and ARG624. The hydrophobic interactions of this
complex occur at the residues identical to H‐bond interactions.
The H‐bond interactions were further shown by catechin while
interacting with HIS250, ASN278, LYS290, SER294, and LEU346 of
EndoU. Besides, the hydrophobic interactions were performed by
interacting with TYR343 and LYS345. Kaempferol was again showing
the best affinity with SER371, ARG408, and GLN409 of S1 protein.
The only hydrophobic interaction was performed by interacting with
PRO384. S2 protein binding site was occupied by apigenin in its best
binding affinity among 20 ligands performing H‐bond interactions
with LYS933, THR719, SER929, and ALA930. There is no hydrophobic
interaction identified in this binding pose. The detail information
about distance and angle of individual H‐bond interactions is pre-
sented in Table 7. H‐bonds can be classified into weak, moderate
and strong H‐bonds depending on its angle and distance. Strong H‐
bonds have the distance range from 2.2 to 2.5 Å and angle between
170 and 180 degree, whereas weak H‐bonds have the distance more8
than 3.2 Å and the angle more than 90 degree. Moderate H‐bonds have
the distance between strong and weak H‐bonds and the angle more
than 130 degree [52].5. Discussion
Carica papaya leaves have been traditionally used to relieve dengue
fever in some Asian countries. The leaves are sliced into smaller pieces
and followed by boiling them into the water for at least 15 min and
then filtered out to collect the liquid phase. This 30 mL of the aqueous
extract is three times daily used for dengue patients until the fever
fully recovered into a normal body temperature [53].
Scientifically, the methanolic extract of Carica papaya leaves
showed cytotoxic effects (CC50 = 0.6156 mg/mL) to LLC‐MK2 cells
and it showed inhibitory activity (EC50 ≥ 1 mg/mL) against DENV‐2
with a selectivity index value of ±>1 [54]. Treatments with
500 mg/kg and 1000 mg/kg of freeze‐dried Carica papaya leaf juice
Fig. 5. The docking pose of a) catechin (−7.7 kcal/mol) into EndoU, b) kaempferol into S1 (−8.2 kcal/mol), and c) apigenin (−6.3 kcal/mol) into S2. The
proteins were visualized in ribbon model, whereas the ligands were presented in a yellow stick model, with C, H, O, and N are colored by yellow, white, red and
blue, respectively. The H-bond interaction and the hydrophobic interaction are presented in black and orange dashed lines, respectively. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 7
The detail information about distance and angle of individual H-bond interactions. The atom type and numbering of each ligands are defined in Table S5.
Targets Ligands Interactions HB distance (Å) HB angles (°) Remark
Mpro deoxyquercetin GLU166:NH – DOQ:O1 2.235 152.940 Moderate
DOQ:H29 – PHE140:O 2.929 91.570 Weak
PLpro riboflavin VAL165:NH – RF:O6 3.050 117.750 Weak
ARG166:NH – RF:O6 2.317 159.880 Moderate
TYR273:H – RF:N9 2.667 92.620 Weak
RF:H46 – ASP302:OD1 2.323 144.660 Moderate
SER245:HB2 – RF:O5 2.567 143.085 Moderate
RdRp kaempferol LYS545:HZ3 – KF:06 1.970 167.720 Moderate
THR556:HG1 – KF:O4 2.910 115.190 Weak
ARG624:HH12 - KF:O4 2.367 107.920 Weak
ARG624:HH22 - KF:O4 2.283 108.620 Weak
EndoU catechin LYS290:HZ3 – CTC:O5 1.960 172.756 Strong
SER294:NH – CTC:O2 2.042 160.573 Moderate
LEU346:NH – CTC:O3 2.108 154.170 Moderate
CTC:H34 – HIS250:NE2 2.312 129.033 Weak
ASN278:HD22 – CTC:O3 2.208 137.886 Moderate
S1 kaempferol GLN409:HE21 – KF:O4 2.820 94.092 Weak
ARG408:HH12 – KF:O2 2.336 135.509 Moderate
ARG408:HH22 – KF:O2 2.247 137.850 Moderate
S2 apigenin LYS933:HZ3 – APG:O1 2.225 147.531 Moderate
THR719:HB – APG:O3 2.615 136.176 Moderate
SER929:HB2 – APG:O4 2.548 119.748 Weak
ALA930:HA – APG:O1 2.892 132.931 Moderate
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mice. A significant decrease (p< 0.05) in viral RNA level was detected
in the liver and kidney of infected AG129 mice treated with 1000 mg/
kg of freeze‐dried Carica papaya leaf juice. Carica papaya treatment
also significantly decreased (p < 0.05) the levels of certain cytokines
and chemokines in plasma, liver, and kidney tissues of infected AG129
mice [55]. A study by Sharma et al. suggested that papaya leaves
extract significantly decreases the expression of the envelope and
NS1 proteins in DENV‐infected THP‐1 cells. This marked a decrease
in intracellular viral load upon the extract treatment confirmed its
antiviral activity [56].
Studies were carried out on natural papain inhibitor from papaya
latex. The isolated fractions, identified as inhibitors I and II, showed
a negative reaction with ninhydrin; however, the fraction identified
as P‐III showed a positive reaction with ninhydrin. Kinetics data
showed non‐competitive inhibition (inhibitor I) and uncompetitive
(inhibitors II and P‐III) [57]. In silico anti‐dengue activities of the
extracts from Carica papaya by using bioinformatics tools were investi-
gated. Interestingly, the flavonoid quercetin performed the highest
binding energy against NS2B‐NS3 protease which is evidenced by
the formation of six hydrogen bonds with the amino acid residues at9
the binding site of the receptor [58]. This is then later proven
by in vitro study, that flavonoid quercetin able to inhibit the DENV2
NS2B‐NS3 protease through a non‐competitive inhibition [59]
In this present study, an integrated in silico screening has been per-
formed against 40 compounds identified from Carica papaya leaves.
The 40 compounds have a diverse scaffold bearing flavonoid, flavanol,
alkaloid, phytosterol, glycoside, phenylpropanoid, carbohydrate, cou-
marin, anthraquinone, and flavin class compounds. These compounds
have their drug‐like likeness, carcinogenicity, toxicity, pharmacokinet-
ics, and pharmacodynamic profiles that contribute to the therapeutic
effect of Carica papaya leaves as discussed above. There had been 20
of those 40 compounds finally selected, which might contribute to
the therapeutic effects better than its toxic properties.
These 20 compounds were predicted to meet the rule of Lipinski,
therefore, they should be stable during oral administration. These
selected compounds should not be carcinogenic, cardiotoxic, hepato-
toxic, and having drug tolerance that lowering the drug safety index.
These compounds also should be well absorbed by the biological mem-
brane and then well distributed into the site of action. Upon therapeu-
tic effects, these compounds should be easily metabolized into an
inactive metabolite and followed by the excretion of chemicals from
P. Hariyono et al. Results in Chemistry 3 (2021) 100113our body system to minimize chemical retention that could be having
adverse drug reactions. Finally, these 20 compounds demonstrated
molecular interactions upon in silico docking them into the diverse pro-
tein targets of SARS‐Coronavirus‐2. According to the binding energy
average, the 20 compounds interact with the protein in a sequence
of higher to lower binding affinity as follows:
S1 > 3CLpro > EndoU > RdRp > PLpro > S2. This means that most
likely, Carica papayamight disrupt the SARS‐Coronavirus‐2 life cycle
by interrupting the binding of spike protein into ACE2 receptor, the
proteolysis of nsp4‐13, and the reverse RNA transcription rather than
inhibiting the RNA replication, proteolysis of nsp1‐3, and the fusion
core in S2 region of spike protein and bringing viral and cellular mem-
branes into proximity for membrane fusion.
The notable compounds' performance in their protein target is most
likely having flavonoid/ flavanol/ flavin scaffold. This is for sure in
correspondence with the previous studies that flavonoid class com-
pound has a pleiotropic effect upon biological targets. By blocking
the S1 protein binding to its ACE2 receptor, flavonoids in Carica
papayamay contribute to its prevention toward the SARS‐
Coronavirus cell invasion. The immunomodulatory effects of Carica
papaya leaves may also work on the target, therefore, this is in agree-
ment with the study by Norahmad et al. The second hypothesis on how
the Carica papaya leaves would eradicate the SARS‐Coronavirus‐2 cell
proliferation is by blocking the 3CLpro enzymatic activity. This is pro-
ven by the therapeutic effect of flavonoid quercetin to inhibit DENV2
NS2B‐NS3 protease which is also a serine protease enzyme as studied
by de Sousa et al [60,61].
The in silico structure‐based drug design has been applied in this
study to speed up the discovery of SARS‐Coronavirus‐2 antiviral agents
using an inexpensive and rational approach [62,63]. Carica papaya is a
natural product which is a highly available and abundant resource that
could lead for an effective and efficient herbal drug [64] to combat
SARS‐Coronavirus‐2 pandemic.
6. Conclusion
In conclusion, Carica papaya leaves have the potential to be the
SARS‐Coronavirus‐2 antiviral agent from herbal. This is due to the
20 compounds presenting in its leaves which have drug‐like likeness
structure, non‐carcinogenic, non‐toxic, pharmacokinetically and phar-
macodynamically stable as predicted by in silico experiments. The
major flavonoid compounds that are interacting with a diverse protein
target of SARS‐Coronavirus‐2, could be the rational reason on how this
herbal would be promising as this antiviral agent.
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